Anticoagulation practices during neonatal extracorporeal membrane oxygenation: survey results.

To ascertain current anticoagulation management during neonatal extracorporeal membrane oxygenation (ECMO), a telephone survey was undertaken of all active ECMO (n = 81, 100% response rate) centres in the USA. Hospital policies regarding federal regulations governing laboratory tests [Clinical Laboratory Improvement Amendment (CLIA) 1988] were determined along with specific patient anticoagulation strategies and use of specific activated coagulation time (ACT) equipment. More than 90% of the respondents use the Hemochron device (International Technidyne Corp, Edison, NJ, USA) while the remaining centres use the Hemotec device (Medtronic Hemotec, Inc, Englewood, CO, USA). Quality control (QC) testing is performed by most centres, but there is no consensus regarding frequency of testing nor methods for dealing with abnormal results. Nearly one-half of the centres use beef lung-derived heparin and the other half use porcine intestinal-derived heparin. One-half of the programmes had a minimum heparin dose despite the ACT value, but the range varied significantly. Four out of five respondents reported that heparin dosages were dictated strictly by ACT results, and 63% will temporarily stop heparin administration for high ACT results, bleeding and/or surgery. Approximately one-third of the centres perform proficiency testing of the equipment in compliance with CLIA 1988. In conclusion, there appears to be no consensus regarding commitment to a QC programme among active ECMO centres.